Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05852522Recruiting

Molecularly Aided Stratification for Tumor Eradication Research

Role: collaborator

NCT04410653Phase 2Completed

Afatinib in Advanced NRG1-Rearranged Malignancies

Role: collaborator

NCT05871593Not ApplicableNot Yet Recruiting

CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01

Role: collaborator

NCT02766686Not ApplicableRecruiting

Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons

Role: collaborator

NCT02189967Not ApplicableCompleted

Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation

Role: collaborator

All 5 trials loaded